Format
Sort by
Items per page

Send to

Choose Destination

Best matches for O’Rear J[au]:

Search results

Items: 1 to 50 of 60

1.

In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.

Komatsu TE, Hodowanec AC, Colberg-Poley AM, Pikis A, Singer ME, O'Rear JJ, Donaldson EF.

Antiviral Res. 2019 Sep;169:104549. doi: 10.1016/j.antiviral.2019.104549. Epub 2019 Jul 4.

PMID:
31279814
2.

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox.

Chan-Tack KM, Harrington PR, Choi SY, Myers L, O'Rear J, Seo S, McMillan D, Ghantous H, Birnkrant D, Sherwat AI.

Lancet Infect Dis. 2019 Jun;19(6):e221-e224. doi: 10.1016/S1473-3099(18)30788-6. Epub 2019 Mar 7. Review.

PMID:
30853252
3.

Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives.

Hodowanec AC, Pikis A, Komatsu TE, Sampson MR, Younis IR, O'Rear JJ, Singer ME.

J Clin Pharmacol. 2019 Jun;59(6):784-798. doi: 10.1002/jcph.1363. Epub 2018 Dec 26. Review.

PMID:
30586161
4.

Offering the Influenza Vaccine in a Pediatric Hand Surgery Clinic Increases Vaccination Rates.

Hutchison RL, O'Rear J, Olson-Burgess C, Myers AL.

J Hand Surg Am. 2018 Aug;43(8):776.e1-776.e4. doi: 10.1016/j.jhsa.2018.01.017. Epub 2018 Mar 16.

PMID:
29551340
5.

Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.

Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'Rear JJ, Naeger LK.

Hepatology. 2018 Jun;67(6):2430-2448. doi: 10.1002/hep.29693.

PMID:
29194682
6.

A selective insecticidal protein from Pseudomonas mosselii for corn rootworm control.

Wei JZ, O'Rear J, Schellenberger U, Rosen BA, Park YJ, McDonald MJ, Zhu G, Xie W, Kassa A, Procyk L, Perez Ortega C, Zhao JZ, Yalpani N, Crane VC, Diehn SH, Sandahl GA, Nelson ME, Lu AL, Wu G, Liu L.

Plant Biotechnol J. 2018 Feb;16(2):649-659. doi: 10.1111/pbi.12806. Epub 2017 Oct 1.

7.

Atypical Vascular Breast Masses.

O'Rear JM, Hufford TA, Peckler MS.

Am Surg. 2017 Jan 1;83(1):e36-38. No abstract available.

PMID:
28234122
8.

Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.

Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ, Harrington PR.

Gastroenterology. 2017 Feb;152(3):586-597. doi: 10.1053/j.gastro.2016.10.017. Epub 2016 Oct 20.

PMID:
27773808
9.

Regulatory evaluation of antiviral drug resistance in the era of next-generation sequencing.

Donaldson EF, Deming DJ, O'Rear JJ, Naeger LK.

Biomark Med. 2015;9(11):1047-51. doi: 10.2217/bmm.15.63. Epub 2015 Oct 28. No abstract available.

10.

Early percutaneous endoscopic gastrostomy tube dislodgment.

OʼRear JM, Prahlow JA.

Am J Nurs. 2015 Jun;115(6):26-31; quiz 32, 46. doi: 10.1097/01.NAJ.0000466312.00767.59.

PMID:
25970629
11.

Factors associated with pulmonary embolism within 72 hours of admission after trauma: a multicenter study.

Coleman JJ, Zarzaur BL, Katona CW, Plummer ZJ, Johnson LS, Fecher A, O'Rear JM, Feliciano DV, Rozycki GS.

J Am Coll Surg. 2015 Apr;220(4):731-6. doi: 10.1016/j.jamcollsurg.2014.12.032. Epub 2015 Jan 6.

PMID:
25724603
12.

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.

Mishra P, Florian J, Qi K, Zeng W, Naeger LK, Donaldson E, Connelly S, O'Rear J, Price D, Murray J, Birnkrant D.

Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27. No abstract available.

PMID:
25449024
13.

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.

Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK.

Hepatology. 2015 Jan;61(1):56-65. doi: 10.1002/hep.27375. Epub 2014 Nov 20.

PMID:
25123381
14.

Standards for sequencing viral genomes in the era of high-throughput sequencing.

Ladner JT, Beitzel B, Chain PS, Davenport MG, Donaldson EF, Frieman M, Kugelman JR, Kuhn JH, O'Rear J, Sabeti PC, Wentworth DE, Wiley MR, Yu GY; Threat Characterization Consortium, Sozhamannan S, Bradburne C, Palacios G.

MBio. 2014 Jun 17;5(3):e01360-14. doi: 10.1128/mBio.01360-14.

15.

Increased fluoroscopy time for central venous catheter placement by radiology residents versus staff radiologists.

Xu BJ, Duszak R Jr, McGinnis RS, Stanfill JG, O'Rear J, An AQ.

J Am Coll Radiol. 2013 Jul;10(7):518-22. doi: 10.1016/j.jacr.2012.12.023.

PMID:
23827004
16.

Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.

Florian J, Jadhav PR, Amur S, Ayala R, Harrington P, Mishra P, O'Rear J, Pacanowski M, Robertson S, Singer M, Soon G, Zeng W, Murray J.

Hepatology. 2013 Mar;57(3):903-7. doi: 10.1002/hep.25843. Epub 2013 Jan 29. No abstract available.

PMID:
22610696
17.

Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.

Liu J, Jadhav PR, Amur S, Fleischer R, Hammerstrom T, Lewis L, Naeger L, O'Rear J, Pacanowski M, Robertson S, Seo S, Soon G, Birnkrant D.

Hepatology. 2013 Mar;57(3):897-902. doi: 10.1002/hep.25764. Epub 2012 Dec 28.

PMID:
22487907
18.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG).

Gastroenterology. 2011 Mar;140(3):755-60. doi: 10.1053/j.gastro.2011.01.029. Epub 2011 Jan 19. No abstract available.

PMID:
21255574
19.

Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.

Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U.

Circ Heart Fail. 2008 Nov;1(4):258-64. doi: 10.1161/CIRCHEARTFAILURE.108.790774. Epub 2008 Oct 14.

PMID:
19808300
20.

Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA.

J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8. Epub 2007 Feb 26.

21.

The precursor to B-type natriuretic peptide is an O-linked glycoprotein.

Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS.

Arch Biochem Biophys. 2006 Jul 15;451(2):160-6. Epub 2006 Apr 19.

PMID:
16750161
22.

KREPA4, an RNA binding protein essential for editosome integrity and survival of Trypanosoma brucei.

Salavati R, Ernst NL, O'Rear J, Gilliam T, Tarun S Jr, Stuart K.

RNA. 2006 May;12(5):819-31. Epub 2006 Apr 6.

23.
24.

Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update.

Lard-Whiteford SL, Matecka D, O'Rear JJ, Yuen IS, Litterst C, Reichelderfer P; International Working Group on Microbicides.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):541-52. Review.

PMID:
15097296
25.

Defects in the N-linked oligosaccharide biosynthetic pathway in a Trypanosoma brucei glycosylation mutant.

Acosta-Serrano A, O'Rear J, Quellhorst G, Lee SH, Hwa KY, Krag SS, Englund PT.

Eukaryot Cell. 2004 Apr;3(2):255-63.

26.

Separate insertion and deletion subcomplexes of the Trypanosoma brucei RNA editing complex.

Schnaufer A, Ernst NL, Palazzo SS, O'Rear J, Salavati R, Stuart K.

Mol Cell. 2003 Aug;12(2):307-19.

27.

TbMP81 is required for RNA editing in Trypanosoma brucei.

Drozdz M, Palazzo SS, Salavati R, O'Rear J, Clayton C, Stuart K.

EMBO J. 2002 Apr 2;21(7):1791-9.

28.

Comparison of the hammerhead cleavage reactions stimulated by monovalent and divalent cations.

O'Rear JL, Wang S, Feig AL, Beigelman L, Uhlenbeck OC, Herschlag D.

RNA. 2001 Apr;7(4):537-45.

29.

Brown midrib sorghum in diets for lactating dairy cows.

Aydin G, Grant RJ, O'Rear J.

J Dairy Sci. 1999 Oct;82(10):2127-35.

30.
31.

Partial characterization of apoptotic factor in Alzheimer plasma.

Maesaka JK, Palaia T, Chowdhury SA, Shimamura T, Fishbane S, Reichman W, Coyne A, O'Rear JJ, El-Sabban ME.

Am J Physiol. 1999 Apr;276(4):F521-7. doi: 10.1152/ajprenal.1999.276.4.F521.

PMID:
10198410
32.

Chinese hamster ovary cells with reduced hexokinase activity maintain normal GDP-mannose levels.

O'Rear JL, Scocca JR, Walker BK, Kaiden A, Krag SS.

J Cell Biochem. 1999 Jan 1;72(1):56-66.

PMID:
10025667
33.

Nonglucosylated oligosaccharides are transferred to protein in MI8-5 Chinese hamster ovary cells.

Quellhorst GJ Jr, O'Rear JL, Cacan R, Verbert A, Krag SS.

Glycobiology. 1999 Jan;9(1):65-72.

PMID:
9884408
34.

Localization of heparin binding activity in recombinant laminin G domain.

Sung U, O'Rear JJ, Yurchenco PD.

Eur J Biochem. 1997 Nov 15;250(1):138-43.

35.

The laminin alpha2-chain short arm mediates cell adhesion through both the alpha1beta1 and alpha2beta1 integrins.

Colognato H, MacCarrick M, O'Rear JJ, Yurchenco PD.

J Biol Chem. 1997 Nov 14;272(46):29330-6.

36.

Dose to the contralateral breast: a comparison of two techniques using the enhanced dynamic wedge versus a standard wedge.

Warlick WB, O'Rear JH, Earley L, Moeller JH, Gaffney DK, Leavitt DD.

Med Dosim. 1997 Fall;22(3):185-91.

PMID:
9307948
37.

Dosimetric parameters of enhanced dynamic wedge for treatment planning and verification.

Leavitt DD, Lee WL, Gaffney DK, Moeller JH, O'Rear JH.

Med Dosim. 1997 Fall;22(3):177-83.

PMID:
9307947
38.

The alpha chain of laminin-1 is independently secreted and drives secretion of its beta- and gamma-chain partners.

Yurchenco PD, Quan Y, Colognato H, Mathus T, Harrison D, Yamada Y, O'Rear JJ.

Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10189-94. Erratum in: Proc Natl Acad Sci U S A 1998 Feb 17;95(4):1968.

39.
40.

Mapping of network-forming, heparin-binding, and alpha 1 beta 1 integrin-recognition sites within the alpha-chain short arm of laminin-1.

Colognato-Pyke H, O'Rear JJ, Yamada Y, Carbonetto S, Cheng YS, Yurchenco PD.

J Biol Chem. 1995 Apr 21;270(16):9398-406.

41.

New vectors for manipulation and selection of functional yeast artificial chromosomes (YACs) containing human DNA inserts.

Emanuel SL, Cook JR, O'Rear J, Rothstein R, Pestka S.

Gene. 1995 Apr 3;155(2):167-74.

PMID:
7721086
42.

A method for total skin electron treatment for infants.

Earley L, Moeller J, O'Rear J, Leavitt DD.

Med Dosim. 1995 Winter;20(4):243-8.

PMID:
8703318
43.

Basal lamina assembly.

Yurchenco PD, O'Rear JJ.

Curr Opin Cell Biol. 1994 Oct;6(5):674-81. Review.

PMID:
7833047
44.

Domain-specific activation of neuronal migration and neurite outgrowth-promoting activities of laminin.

Calof AL, Campanero MR, O'Rear JJ, Yurchenco PD, Lander AD.

Neuron. 1994 Jul;13(1):117-30.

45.
46.

Basement membrane assembly.

Yurchenco PD, O'Rear JJ.

Methods Enzymol. 1994;245:489-518. No abstract available.

PMID:
7760748
47.

Cell and heparin binding in the distal long arm of laminin: identification of active and cryptic sites with recombinant and hybrid glycoprotein.

Sung U, O'Rear JJ, Yurchenco PD.

J Cell Biol. 1993 Dec;123(5):1255-68. Erratum in: J Cell Biol 1993 Dec;123(6 Pt 1):1623.

48.

Recombinant laminin G domain mediates myoblast adhesion and heparin binding.

Yurchenco PD, Sung U, Ward MD, Yamada Y, O'Rear JJ.

J Biol Chem. 1993 Apr 15;268(11):8356-65.

49.

A novel laminin B1 chain variant in avian eye.

O'Rear JJ.

J Biol Chem. 1992 Oct 15;267(29):20555-7.

Supplemental Content

Loading ...
Support Center